{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:38:38Z","timestamp":1790735918539,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T00:00:00Z","timestamp":1622246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking","award":["821283"],"award-info":[{"award-number":["821283"]}]},{"name":"National Institute of Health Research Nottingham Digestive Diseases Biomedical Research Unit and Nottingham Biomedical Research Centre","award":["BRC-1215-20003"],"award-info":[{"award-number":["BRC-1215-20003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Zanubrutinib is a Bruton\u2019s tyrosine kinase inhibitor that has been recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are no reported cases of hepatotoxicity secondary to zanubrutinib. We report the first case of severe liver injury due to zanubrutinib.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 56-year-old Caucasian male with a history of relapsed lymphoplasmacytic lymphoma was admitted to the hospital with new-onset jaundice, choluria, and pruritus for 10\u00a0days. He had been on zanubrutinib as part of a clinical trial for 30 months. His blood profile showed a severe hepatocellular injury with jaundice (alanine transaminase 2474 IU\/L and total bilirubin 141 umol\/L with mild coagulopathy). He had an extensive work-up including virology, autoimmune, and metabolic profiles in addition to abdominal ultrasound with no alternative explanation found for his liver injury. Zanubrutinib-induced liver injury was suspected, and causality assessment by the updated Roussel Uclaf Causality Assessment Method score showed a probable causal relationship with zanubrutinib. His liver histology was also consistent with drug-induced liver injury. His liver biochemistry improved following cessation of zanubrutinib and normalised after 8\u00a0weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We report the first case of severe liver injury secondary to zanubrutinib after 30 months of treatment. This case raises clinical awareness regarding zanubrutinib-induced liver toxicity and the importance of drug withdrawal in the event of liver injury.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-01825-2","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T08:10:49Z","timestamp":1624435849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Zanubrutinib-induced liver injury: a case report and literature review"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-9174","authenticated-orcid":false,"given":"Edmond","family":"Atallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramudi","family":"Wijayasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khorrum","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1828-4155","authenticated-orcid":false,"given":"Abhik","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3924-4830","authenticated-orcid":false,"given":"Guruprasad P.","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,29]]},"reference":[{"issue":"2","key":"1825_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/00042737-200502000-00002","volume":"17","author":"D Larrey","year":"2005","unstructured":"Larrey D, Pageaux GP. Drug-induced acute liver failure. Eur J Gastroenterol Hepatol. 2005;17(2):141\u20133.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1825_CR2","doi-asserted-by":"crossref","unstructured":"Lee WM. Drug-induced acute liver failure. Clin Liver Dis. 2013;17(4):575\u201386, viii.","DOI":"10.1016\/j.cld.2013.07.001"},{"issue":"1","key":"1825_CR3","doi-asserted-by":"publisher","first-page":"e004221","DOI":"10.1136\/bmjopen-2013-004221","volume":"4","author":"R McNaughton","year":"2014","unstructured":"McNaughton R, Huet G, Shakir S. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making. BMJ Open. 2014;4(1):e004221.","journal-title":"BMJ Open"},{"key":"1825_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","volume":"14","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.","journal-title":"BMC Med"},{"key":"1825_CR5","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver. Electronic address, E.E.E., et al. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222\u20131261.","DOI":"10.1016\/j.jhep.2019.02.014"},{"issue":"1","key":"1825_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/ijms17010014","volume":"17","author":"G Danan","year":"2016","unstructured":"Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1825_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/ajh.25292","volume":"94","author":"MA Gertz","year":"2019","unstructured":"Gertz MA. Waldenstrom macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(2):266\u201376.","journal-title":"Am J Hematol"},{"issue":"1","key":"1825_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.","journal-title":"Mol Cancer"},{"issue":"18","key":"1825_CR9","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood.2020006844","volume":"136","author":"CS Tam","year":"2020","unstructured":"Tam CS, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood. 2020;136(18):2038\u201350.","journal-title":"Blood"},{"key":"1825_CR10","unstructured":"Multi-disciplinary Review and Evaluation NDA 213217 - BRUKINSA (zanubrutinib). 2019."},{"key":"1825_CR11","unstructured":"BRUKINSA\u2122 (zanubrutinib) FDA PRESCRIBING INFORMATION. 2019."},{"issue":"11","key":"1825_CR12","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851\u20139.","journal-title":"Blood"},{"issue":"4","key":"1825_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","volume":"127","author":"HS Walter","year":"2016","unstructured":"Walter HS, et al. A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411\u20139.","journal-title":"Blood"},{"issue":"6","key":"1825_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ccr3.881","volume":"5","author":"AG Nandikolla","year":"2017","unstructured":"Nandikolla AG, et al. Ibrutinib-induced severe liver injury. Clin Case Rep. 2017;5(6):735\u20138.","journal-title":"Clin Case Rep"},{"issue":"2","key":"1825_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/10428194.2017.1346251","volume":"59","author":"A Kahn","year":"2018","unstructured":"Kahn A, et al. Ibrutinib-induced acute liver failure. Leuk Lymphoma. 2018;59(2):512\u20134.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1825_CR16","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.1097\/HS9.0000000000000307","volume":"3","author":"FS Kleijwegt","year":"2019","unstructured":"Kleijwegt FS, et al. Rare but serious: ibrutinib induced liver failure. Hemasphere. 2019;3(6):e307.","journal-title":"Hemasphere"},{"issue":"2","key":"1825_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000502605","volume":"13","author":"ZH Tafesh","year":"2019","unstructured":"Tafesh ZH, et al. Severe hepatotoxicity due to ibrutinib with a review of published cases. Case Rep Gastroenterol. 2019;13(2):357\u201363.","journal-title":"Case Rep Gastroenterol"},{"key":"1825_CR18","unstructured":"WHO global pharmacovigilance center. http:\/\/www.vigiaccess.org. Accessed 3 Dec 2020."},{"issue":"3","key":"1825_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/hep.24481","volume":"54","author":"A Suzuki","year":"2011","unstructured":"Suzuki A, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54(3):931\u20139.","journal-title":"Hepatology"},{"issue":"17","key":"1825_CR20","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1182\/blood-2018-01-826495","volume":"131","author":"SP Hammond","year":"2018","unstructured":"Hammond SP, et al. Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018;131(17):1987\u20139.","journal-title":"Blood"},{"issue":"7","key":"1825_CR21","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491\u2013503.","journal-title":"Drug Saf"},{"issue":"8","key":"1825_CR22","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.3390\/ijms19082367","volume":"19","author":"KD Jackson","year":"2018","unstructured":"Jackson KD, Durandis R, Vergne MJ. Role of cytochrome P450 enzymes in the metabolic activation of tyrosine kinase inhibitors. Int J Mol Sci. 2018;19(8):2367.","journal-title":"Int J Mol Sci."},{"issue":"3","key":"1825_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jat.3551","volume":"38","author":"C Mingard","year":"2018","unstructured":"Mingard C, et al. Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. J Appl Toxicol. 2018;38(3):418\u201331.","journal-title":"J Appl Toxicol"},{"key":"1825_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fphar.2017.00367","volume":"8","author":"F Paech","year":"2017","unstructured":"Paech F, Bouitbir J, Krahenbuhl S. Hepatocellular toxicity associated with tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis. Front Pharmacol. 2017;8:367.","journal-title":"Front Pharmacol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01825-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01825-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T09:14:51Z","timestamp":1625562891000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01825-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,29]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1825"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01825-2","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,29]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}],"article-number":"244"}}